Collagenase specificity in chondrosarcoma metastasis

Brazilian Journal of Medical and Biological Research

Volumn 32, Issue 7, 1999, Pages 885-889

  Scully, S P ^a   Berend, K R ^a   Qi, W N ^a   Harrelson, J M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chondrosarcoma; Collagenase; Gene expression; Metastasis; Prognosis

Indexed keywords

COLLAGENASE;

ARTICLE; BONE TUMOR; CHONDROSARCOMA; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ENZYME SPECIFICITY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METASTASIS; PROGNOSIS;

BONE NEOPLASMS; CHONDROSARCOMA; COLLAGENASES; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; PROGNOSIS; SUBSTRATE SPECIFICITY;

EID: 0033162286     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X1999000700013     Document Type: Article

References (39)

1. Brien EW, Mirra JM & Kerr R (1997). Benign and malignant cartilage tumors of bone and joint - their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. 1. The intramedullary cartilage tumors (Review). Skeletal Radiology, 26: 325-353.
2. Bridge JA, DeBoer J, Travis J, Johansson SL, Elmberger G, Noel SM & Neff JR (1994). Simultaneous interphase cytogenetic analysis and fluorescence immunophenotyping of dedifferentiated chondrosarcoma. Implications for histopathogenesis. American Journal of Pathology, 144: 215-220.
3. Bridge JA, Bhatia PS, Anderson JR & Neff JR (1993). Biologic and clinical significance of cytogenetic and molecular cytogenetic abnormalities in benign and malignant cartilaginous lesions. Cancer Genetics and Cytogenetics, 69: 79-90.
4. Castresana JS, Barrios C, Gomez L & Kreicbergs A (1992). Amplification of the c-myc proto-oncogene in human chondrosarcoma. Diagnostic Molecular Pathology, 1: 235-238.
5. Choong PFM, Rydholm A, Mertens F & Mandahl N (1997). Musculoskeletal oncology - advances in cytogenetics and molecular genetics and their clinical implications (Review). Acta Oncologica, 36: 245-254.
6. Coughlan B, Feliz A, lshida T, Czerniak B & Dorfman HD (1995). p53 expression and DNA ploidy of cartilage lesions. Human Pathology, 26: 620-624.
7. Crim JR & Seeger LL (1993). Diagnosis of low-grade chondrosarcoma. Radiology, 189: 503; discussion 504.
8. Dijkhuizen T, van den Berg E, Molenaar WM, Oosterhuis JW, Dam A, Wiersema J, Schraffordt Koops H & de Jong B (1994). Cytogenetics as a tool in the histologie subclassification of chondrosarcomas. Cancer Genetics and Cytogenetics, 76: 100-105.
9. Dobashi Y, Sugimura H, Sato A, Hirabayashi T, Kanda H, Kitagawa T, Kawaguchi N, Imamura T & Machinami R (1993). Possible association of p53 overexpression and mutation with high-grade chondrosarcoma. Diagnostic Molecular Pathology, 2: 257-263.
10. Hasegawa T, Seki K, Yang P, Hirose T, Hizawa K, Wada T & Wakabayashi J (1995). Differentiation and proliferative activity in benign and malignant cartilage tumors of bone. Human Pathology, 26: 838-845.
11. Helio H, Karaharju E, Bohling T, Kivioja A & Nordling S (1995). Chondrosarcoma of bone. A clinical and DNA flow cytometric study. European Journal of Surgical Oncology, 21: 408-413.
12. Larramendy ML, Tarkkanen M, Valle J, Kivioja AH, Ervasti H, Karaharju E, Salmivalli T, Elomaa I & Knuutila S (1997). Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. American Journal of Pathology, 150: 685-691.
13. Nawa G, Ueda T, Mori S, Yoshikawa H, Fukuda H, Ishiguro S, Funai H & Uchida A (1996). Prognostic significance of Ki67 (MIB1) proliferation index and p53 overexpression in chondrosarcomas. International Journal of Cancer, 69: 86-91.
14. Orndal C, Mandahl N, Rydholm A, Willen H, Brosjo O & Mitelman F (1993). Chromosome aberrations and cytogenetic intratumor heterogeneity in chondrosarcomas. Journal of Cancer Research and Clinical Oncology, 120: 51-56.
15. Rosier RN, Okeefe RJ, Teot LA, Fox EJ, Nester TA, Puzas JE, Reynolds PR & Hicks DG (1997). P-Glycoprotein expression in cartilaginous tumors. Journal of Surgical Oncology, 65: 95-105.
16. Scully S (1997). Prognostic markers in chondrosarcoma: evaluation of cell proliferation and regulators of the cell cycle. Sarcoma, 1: 79-87.
17. Shih CS, Wang LS, Yang SS, Fahn HJ, Wu LH, Chen WYK & Huang MH (1996). DNA flow cytometric analysis of chest-wall chondroma and chondrosarcoma. Scandinavian Journal of Thoracic and Cardiovascular Surgery, 30: 157-161.
18. Simms WW, Ordonez NG, Johnston D, Ayala AG & Czerniak B (1995). p53 expression in dedifferentiated chondrosarcoma. Cancer, 76: 223-227.
19. Sogawa K, Yamada T, Funamoto Y, Kohno K, Nishikawa H, Kishida F, Hamazaki F, Yamashita N & Matsumoto K (1994). Selective increase in expression of isoform PP1 gamma 1 of type-1 protein phosphatase in chondrosarcoma cells. Research Communications in Molecular Pathology and Pharmacology, 86: 375-378.
20. Sogawa K, Yamada T, Oka S, Kawasaki K, Mori S, Tanaka H, Norimatsu H, Cai Y, Kuwabara H & Shima H (1995). Enhanced expression of catalytic subunit isoform PP1 gamma 1 of protein phosphatase type 1 associated with malignancy of osteogenic tumor. Cancer Letters, 89: 1-6.
21. Swarts SJ, Neff JR, Johansson SL & Bridge JA (1996). Cytogenetic analysis of dedifferentiated chondrosarcoma. Cancer Genetics and Cytogenetics, 89: 49-51.
22. Werner M, Rieck J, Heintz A, Posl M & Delling G (1996). Comparative DNA-cytometric and cytogenetic determination of ploidy in chondrosarcomas and osteosarcomas (German). Pathologe, 17: 374-379.
23. Yamaguchi T, Toguchida J, Wadayama B, Kanoe H, Nakayama T, Ishizaki K, Ikenaga M, Kotoura Y & Sasaki MS (1996). Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas. Anticancer Research, 16: 2009-2015.
24. Berend KBJ & Scully SP (1998). Metalloproteinase gene expression as a prognostic indicator for survival in patients with chondrosarcoma. Journal of Bone and Joint Surgery, 80A: 11-17.
25. Moses MA & Shing Y (1994). Production of matrix metalloproteinases and a metalloproteinase inhibitor by swarm rat chondrosarcoma. Biochemical and Biophysical Research Communications, 199: 418-424.
26. Schoedel KE, Ohori NP, Greco A & Steiner GC (1997). Expression of metalloproteinases and tissue inhibitor in cartilaginous neoplasms of bone. Applied Immunohistochemistry, 5: 111-116.
27. Kawashima A, Okada Y, Nakanishi I, Ueda Y, Iwata K & Roessner A (1997). Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. General and Diagnostic Pathology, 142: 129-137.
28. Cole AA, Chubinskaya S, Schumacher B, Huch K, Szabo G, Yao J, Mikecz K, Hasty KA & Kuettner KE (1996). Chondrocyte matrix metalloproteinase-8. Human articular chondrocytes express neutrophil collagenase. Journal of Biological Chemistry, 271: 11023-11026.
29. Shlopov BV, Lie WR, Mainardi CL, Cole AA, Chubinskaya S & Hasty KA (1997). Osteoarthritic lesions: involvement of three different collagenases. Arthritis and Rheumatism, 40: 2065-2074.
30. Fosang AJ, Last K & Maciewicz RA (1996). Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. Journal of Clinical Investigation, 98: 2292-2299.
31. Arner EC, Decicco CP, Cherney R & Tortorella MD (1997). Cleavage of native cartilage aggrecan by neutrophil collagenase (MMP-8) is distinct from endogenous cleavage by aggrecanase. Journal of Biological Chemistry, 272: 9294-9299.
32. Gomisruth FX, Gohlke U, Betz M, Knauper V, Murphy G, Lopezotin C & Bode W (1996). The helping hand of collagenase-3 (Mmp-13) - 2.7 angstrom crystal structure of its C-terminal haemopexin-like domain. Journal of Molecular Biology, 264: 556-566.
33. Lemaitre V, Jungbluth A & Eeckhout Y (1997). The recombinant catalytic domain of mouse collagenase-3 depolymerizes type I collagen by cleaving its aminotelopeptides. Biochemical and Biophysical Research Communications, 230: 202-205.
34. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF & Hambor JE (1996). Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. Journal of Clinical investigation, 97: 761-768.
35. Knauper V, Lopez-Otin C, Smith B, Knight G & Murphy G (1996). Biochemical characterization of human collagenase-3. Journal of Biological Chemistry, 271: 1544-1550.
36. Ueda Y, Oda Y, Tsuchiya H, Tomita K & Nakanishi I (1990). Immunohistological study on collagenous proteins of benign and malignant human cartilaginous tumours of bone. Virchows Archiv. A, Pathological Anatomy and Histopathology, 417: 291-297.
37. Kawashima A, Ueda Y, Tsuchiya H, Tomita K, Nagai Y & Nakanishi I (1993). Immunohistochemical localization of collagenous proteins in cartilaginous tumors: characteristic distribution of type IX collagen. Journal of Cancer Research and Clinical Oncology, 120: 35-40.
38. Huang GQ & Steiner GC (1989). Immunohistochemical localization of type II collagen in cartilage-forming tumors. Bulletin of the Hospital for Joint Diseases Orthopaedic Institute, 49: 94-102 (published erratum appears in Bulletin of the Hospital for Joint Diseases Orthopaedic Institute, 1990 Spring; 50(1): 69).
39. Aigner T, Dertinger S, Vornehm SI, Dudhia J, Vondermark K & Kirchner T (1997). Phenotypic diversity of neoplastic chondrocytes and extracellular matrix gene expression in cartilaginous neoplasms. American Journal of Pathology, 150: 2133-2141.